We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

CEVEC and VPM Sign Exclusive License Agreement

News   Jan 04, 2013

 
CEVEC and VPM Sign Exclusive License Agreement
 
 
 

RELATED ARTICLES

Paradigm Shift for Design of Universal Vaccines

News

Killer T cells have been identified that can fight all influenza viruses – A, B and C – creating the potential for the development of a world-first universal, one-shot flu vaccine.

READ MORE

Machine Learning Swiftly Analyzes Nanomedicines for Cancer Immunotherapy

News

With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.

READ MORE

Cracking a One-Two Punch Against Melanoma

News

Updated, safer versions of diphtheria fusion toxin DAB-IL-2 show promise in reducing tumor growth.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE